Trial · NCT02704364
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in alkaline phosphatase levels. |
| Secondary | Mean Percent Change From Baseline in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in alkaline phosphatase levels. |
| Secondary | Mean Rate of Change in Alkaline Phosphatase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess rate of change in alkaline phosphatase levels. Serum levels of alkaline phosphatase was measured in a central laboratory using standard enzymatic method. The unit of measure is U/L. |
| Secondary | Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in aspartate aminotransferase and alanine aminotransferase levels. |
| Secondary | Mean Percent Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in aspartate aminotransferase and alanine aminotransferase levels. |
| Secondary | Mean Change From Baseline in Bilirubin (Direct and Total) in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in bilirubin (direct and total) levels. |
| Secondary | Mean Percent Change From Baseline in Bilirubin (Direct and Total) in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in bilirubin (direct and total) levels. |
| Secondary | Mean Change From Baseline in Gamma Glutamyl Transferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in gamma glutamyl transferase levels. |
| Secondary | Mean Percent Change From Baseline in Gamma Glutamyl Transferase in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in gamma glutamyl transferase levels. |
| Secondary | Mean Change From Baseline in Cholesterol Levels in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in cholesterol levels. |
| Secondary | Mean Percent Change From Baseline in Cholesterol Levels in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in cholesterol levels. |
| Secondary | Mean Change From Baseline in 25-Hydroxyvitamin D in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in 25-Hydroxyvitamin D levels. |
| Secondary | Mean Percent Change From Baseline in 25-Hydroxyvitamin D in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in 25-Hydroxyvitamin D levels. |
| Secondary | Mean Change From Baseline in Prothrombin International Normalized Ratio in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in Prothrombin levels. |
| Secondary | Mean Percent Change From Baseline in Prothrombin International Normalized Ratio in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in Prothrombin levels. |
| Secondary | Mean Change From Baseline in Calprotectin in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Blood samples were collected to assess changes in Calprotectin levels. |
| Secondary | Mean Change From Baseline in Enhanced Liver Fibrosis Score in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Enhanced Liver Fibrosis (ELF) score is a non-invasive blood test derived from the measurement of hyaluronic acid (HA), amino terminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of metalloprotease 1 (TIMP1) using a proprietary algorithm (Siemens). ELF score is a laboratory test, is unitless, and is used as a continuous variable. The minimal ELF score is zero, the maximal ELF score is unknown. The higher the ELF score, the worse the disease outcome. ELF is a score on a scale of severity assessment against biopsy-proven fibrosis. A score of \<7.7 is none to mild, \> 7.7-9.8 is moderate, \> 9.8 is severe. |
| Secondary | Severity of Inflammatory Bowel Disease-Associated Intestinal Symptoms in Patients With Primary Sclerosing Cholangitis | Baseline to Week 12 | Severity of inflammatory bowel disease (IBD)-associated symptoms and acute cholangitis are summarized with number and percentage. The partial Mayo IBD scale assesses stool frequency, rectal bleeding, and there is a Physician's global assessment. Each section is summed and remission is defined as a total score of 0-1, mild disease 2-4, moderate disease 5-6, and severe disease 7-9. Higher total scores indicate more severe disease. The number of participants are being presented based on the severity of their IBD symptoms. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02704364/registered